A single-center, randomized controlled trial involving 170 proteinuric IgAN (90% were biopsy proven) with mean age of 36.6 years and eGFR between 30-60 on maximal ACE were randomized to MMF or standard of care. Primary endpoints included doubling of serum creatinine, ESKD requiring dialysis, death due to renal or cardiovascular cause and progression of CKD. The MMF group had a 77% reduction in reaching primary endpoints versus standard of care, with a median follow up time of 60 months and without significant adverse events
